A combination of therapies may prove to be a promising advance for the treatment of anaplastic thyroid cancer based on results of a phase I clinical trial, say researchers at Mayo Clinic in Florida. The collaborative study reports that combining paclitaxel chemotherapy with an experimental agent known as efatutazone was safe and well tolerated by patients. Read more here.
Study mentioned: Smallridge RC, et al. Efatutazone, an Oral PPAR-γ Agonist, in Combination with Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial. J Clin Endocrinol Metab. 2013 Apr 15. [Epub ahead of print] PMID: 23589525
No comments:
Post a Comment